IVF Failure: Common Causes and What They Mean for Next Steps
Key Takeaways
An IVF cycle can stop at different stages. One negative result rarely names a single cause. The useful next step is a structured review of ovarian response, fertilisation, embryo development, the transfer and prior tests. It helps decide what should change and what should stay.
Key evidence: ASRM — Fertility evaluation of infertile women (2026) ESHRE — Good practice recommendations on recurrent implantation failure (2023) ASRM — Recurrent implantation failure: committee opinion (2026)
A negative pregnancy test after IVF often leaves one question: why did this happen, and what does it mean next?
Start by naming the stage where the cycle stopped: weaker ovarian response than expected, low fertilisation, embryos that stopped developing, no implantation, or an early pregnancy that did not continue. These outcomes do not share the same causes or the same next steps.
The aim is not to assign blame. It is to see what this cycle showed, what remains uncertain, and whether anything specific needs to change.
Embryo Factors and Chromosomal Competence
Whether an embryo implants and keeps developing depends strongly on its chromosomes and on how it has developed.
Age-related aneuploidy — an abnormal number of chromosomes — is generally believed to be the principal cause of implantation failure. That is the position of the American Society for Reproductive Medicine (ASRM) in its 2026 opinion on recurrent implantation failure. An embryo can look excellent under the microscope and still carry a chromosomal problem that its appearance cannot show.
The reverse also matters. A lower morphological grade does not prove that an embryo is chromosomally abnormal. Grading helps the laboratory choose between available embryos. It is not a genetic diagnosis or a promise of outcome.
Preimplantation genetic testing for aneuploidy (PGT-A) may answer a different question in selected patients. But ASRM notes that its value as a routine screening test for everyone having IVF has not been demonstrated.
Maternal Age and Ovarian Reserve
Female age is strongly linked to embryo aneuploidy and IVF prognosis. Ovarian reserve tests mainly estimate how many eggs a cycle is likely to yield.
As age increases, the share of aneuploid embryos generally rises. That shifts the probability of each cycle without delivering a personal verdict.
The ASRM opinion on fertility evaluation explains that anti-Müllerian hormone (AMH) and antral follicle count help anticipate ovarian response. Antral follicles are the small follicles counted on ultrasound. Used alone, these tests predict reproductive potential poorly, so they are read with age, treatment history and the cycle record.
Sperm Quality and Fertilisation Dynamics
Unexpectedly low fertilisation or poor embryo development calls for a look at the semen findings and the fertilisation method.
Sperm concentration, movement (motility) and shape (morphology) belong in the couple’s evaluation. On their own they do not explain every arrest in embryo development. Egg, sperm and laboratory factors can overlap, so the cycle record needs to be read as a whole.
Further male evaluation may be appropriate when the history, semen analysis or fertilisation pattern gives a reason. It should not automatically become a long list of add-on tests. The ASRM committee opinion on recurrent implantation failure finds insufficient evidence to recommend sperm DNA fragmentation testing routinely in patients with recurrent implantation failure.
Uterine Receptivity and the Cavity Environment
Uterine or tubal findings can matter, but they do not automatically justify hysteroscopy, biopsy or a broad receptivity work-up after every negative transfer.
Findings that may change management include:
- Endometrial polyps and cavity-distorting submucosal fibroids
- Intrauterine adhesions (Asherman’s syndrome) or congenital uterine septa
- Hydrosalpinx, in which a fallopian tube is blocked and distended with fluid
- Adenomyosis or endometriosis when the diagnosis and clinical context are relevant
- Chronic endometritis in selected patients with recurrent failure; tests and diagnostic thresholds are not standardised
Whether the cavity needs reassessment depends on previous imaging, symptoms, lining development and the number and type of failed transfers. For practical details, see endometrial thickness before embryo transfer.
The European Society of Human Reproduction and Embryology (ESHRE) good practice recommendations define recurrent implantation failure by a patient’s own cumulative predicted chance of implantation. They do not use a fixed number of failures. The newer ASRM opinion likewise generally reserves the term for failure after several good-quality blastocyst transfers (embryos cultured to about day 5 or 6), not after one unsuccessful transfer.
Biological Probability and Implantation Limits
A single failed embryo transfer does not prove an undiscovered disease or an incorrect protocol.
Human reproduction is probabilistic. Even a euploid embryo — one with a normal chromosome set — can fail to implant. One outcome cannot show whether the explanation was embryo biology, the uterine environment or chance.
A pregnancy that began and then ended raises different questions, and repeated losses are evaluated separately from implantation failure. To read about trying again afterwards, see conceiving after an early miscarriage.
Evidence box: how guidelines frame “recurrent” failure
ASRM and ESHRE do not define “recurrent” in the same way. ASRM counts the good-quality blastocyst transfers needed to reach a 95% cumulative chance of a positive pregnancy test. The number of transfers depends on age and on whether the embryos were chromosomally tested. Cumulative means the combined chance across several transfers. ESHRE uses a 60% cumulative predicted chance of implantation as the point to discuss further investigation. Neither sets one fixed number of failures for everyone.
After genuinely recurrent failure, a focused assessment may be reasonable. A 2024 literature review by Kuroda discusses possible tests after euploid embryo transfer failure. It is not a universal protocol. Any test should be chosen according to the patient’s own findings and current guidelines.
Practical Next Steps: What Changes After a Failed Cycle?
The next step follows the stage where the cycle stopped and the evidence already available. A targeted change may be the answer. So may a repeat attempt without a broad new work-up.
Depending on where the cycle met difficulty, your fertility specialist may recommend:
- Reviewing ovarian response, egg maturity and the stimulation record
- Reviewing fertilisation, embryo development and laboratory observations
- Checking whether previous uterine and tubal imaging remains adequate
- Reassessing semen results or seeking andrology input when there is a specific indication
- Repeating the transfer plan when the record does not reveal a modifiable problem
A good review ends with a short list: what was learned, what will change, what will stay the same, and why. Our guide to what to review after an unsuccessful IVF cycle walks through that conversation in more detail.
Dr. Aksoy’s Approach
After an unsuccessful cycle, I first ask whether the outcome fits the embryo’s natural biological limits or whether the cycle reveals a modifiable problem.
Findings that may change the stimulation protocol, the laboratory strategy or further evaluation include unexpectedly low fertilisation for the clinical context, a higher-than-expected share of immature eggs, marked embryo attrition between days 3 and 5, a difficult transfer or a problem inside the cavity, hydrosalpinx, a cavity-distorting fibroid or polyp, clinically significant endometriosis or adenomyosis, inadequate endometrial development, or severe male-factor infertility.
If ovarian response, egg maturity, fertilisation, embryo development, the uterine assessment and the transfer conditions were all reassuring, one negative transfer is more often compatible with embryo chromosomal biology and probability than with a correctable cause. In that situation, I favour keeping the sound core of the plan and trying again to build cumulative probability, rather than adding indiscriminate tests or treatments supported by limited evidence.
This clinical approach was recorded on 26 August 2026.
Frequently Asked Questions for Dr. Aksoy
Why can IVF fail with embryos that looked high quality? What is the difference between embryo grade and chromosomes?
I often hear this: “The embryo was said to be high quality — why did it not implant?” Looking good under the microscope does not necessarily mean the chromosomes are normal. When we grade an embryo we look at cell appearance, the pace of development and the structure of the blastocyst. Those features do not give definite information about the chromosomes.
As female age rises, we more often see chromosome problems even in morphologically very good embryos. Even a chromosomally normal embryo is not guaranteed to create a pregnancy at every transfer. Problems inside the cavity, how the lining was prepared or the timing of progesterone can also matter. Even so, it is not right to automatically look for a uterine problem after a single failed transfer.
I tell patients that high quality means higher pregnancy potential, not a guarantee — and that failure does not necessarily mean something was done wrong.
After a failed IVF cycle, what does “poor egg quality” mean, and how does it change the next plan?
I think the phrase “poor egg quality” is sometimes used too readily. We cannot measure egg quality with certainty by one test or by microscope appearance alone. Retrieving fewer eggs does not, by itself, prove that the eggs were of poor quality; that finding may say more about ovarian reserve.
When I judge quality I look at the maturation rate, fertilisation results, embryo development and, above all, the woman’s age. Having few embryos, or no blastocyst, in a first attempt also does not prove that all of the eggs were of poor quality.
Before the next cycle I reassess the drug doses used, the timing of the trigger injection, how many mature eggs were obtained, the sperm factor and the laboratory results. I change the protocol if needed, but I do not think it is right to add different drugs or supplements after every failed attempt. I particularly stress this: today we do not have a medicine proven to reliably improve the chromosomal quality of eggs. The aim is to use the existing ovarian potential as well as we can.
After a first failed IVF attempt, when do you widen the work-up, and when do you repeat the same treatment?
I do not start a wide work-up straight away after a first failed IVF attempt. One failure is not unexpected, especially if we do not know the chromosomes of the transferred embryo. First I review each stage: how the ovaries responded to the drugs, how many mature eggs were obtained, how fertilisation and embryo development went, whether the transfer was technically straightforward, and whether the lining and progesterone support were appropriate.
If those stages went as expected and I do not find a clear problem, repeating the same approach can often be the soundest choice. I widen the work-up when there is clear fertilisation failure, a much lower ovarian response than expected, a suspicious finding inside the cavity, or repeated failures.
Even then I do not order immune tests, NK-cell panels, ERA or microbiome tests automatically for every patient, because routine use of most of these tests has not been shown to raise the live birth rate. The point is not to invent a new treatment after every failure, but to see whether there is a problem we can change. Sometimes the right decision is to run a well-planned treatment again.
A first failed IVF cycle is not the same as a first failed embryo transfer. If no embryo developed, earlier review of the protocol and the laboratory may be needed. A single failed blastocyst transfer that otherwise went smoothly often does not call for a wide work-up.
FAQ: more questions about testing after failure
Does an unsuccessful cycle indicate an immune system disorder?
No. Current guidelines do not support routine immune testing or routine immunological therapies after implantation failure, because evidence that they improve the chance of a live birth (a baby born alive) is insufficient. For further reading, see immunological treatments and IVF implantation failure.
Sources
- American Society for Reproductive Medicine. Fertility evaluation of infertile women: a committee opinion. Fertil Steril. 2026. doi:10.1016/j.fertnstert.2026.08.686.
- Practice Committee of the American Society for Reproductive Medicine. Recurrent implantation failure: a committee opinion. Fertil Steril. 2026.
- Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. The use of preimplantation genetic testing for aneuploidy: a committee opinion. Fertil Steril. 2024;122:421-434.
- ESHRE Working Group on Recurrent Implantation Failure. Good practice recommendations on recurrent implantation failure. Hum Reprod Open. 2023;2023(3):hoad023.
- Kuroda K. Management strategies following implantation failure of euploid embryos. Reprod Med Biol. 2024;23(1):e12576. doi:10.1002/rmb2.12576.
Add as a Preferred Source on Google
You can add draksoyivf.com as one of your preferred health information sources on Google.
The content has been created by Dr. Senai Aksoy and medically approved.